Covered to the cent — no cushion. A quarterly payer at $0.24 a share, $0.96 annualized, raised from $0.21 in the third quarter of 2025 and $0.19 through 2024 — and second-quarter 2026 earnings available for distribution (EAD) of $0.24 a share covered the $0.24 dividend exactly, with nothing left over. That is coverage, but it is coverage with no margin: one soft quarter in non-agency residential credit, and the dividend is the question. Book value did rise in the quarter, from $9.97 to $10.00 a share, for a 2.7% economic return including the dividend, and economic leverage of 1.8× is low for a mortgage REIT — but the headline yield is ~17.6% only because the price has fallen, down about 36% year to date to the $5.44 close on October 23, 2026. A 17.6% yield that is exactly covered is a warning, not a bargain, and it carries the mortgage-REIT re-grade trigger: if EAD slips below the dividend, this card is re-graded.
Key risk: Rates, spreads and credit in non-agency residential loans — EAD is exactly the dividend, so any spread widening, funding-cost rise or credit slip in the $7.7 billion portfolio lands straight on coverage, and the pending Cherry Hill acquisition adds leverage and complexity before it adds earnings.
Changes if: EAD falls below the $0.24 quarterly dividend, book value falls for a second straight quarter, or economic leverage rises materially past 1.8×. Any of those turns exact coverage into a cut question.
- !EAD coverage check: Second-quarter 2026 EAD of $0.24 a share covered the $0.24 dividend by $0.00 — 100% paid out, exactly. GAAP net income was $0.29 a share in the quarter, but EAD, not GAAP income, is the mortgage REIT coverage measure.
- ✓Book-value check: Book value rose from $9.97 to $10.00 a share in the second quarter, up 0.3%, for a 2.7% economic return including the $0.24 dividend — book growing, not melting, while the dividend was held and then raised.
- !Leverage check: Economic leverage of 1.8× at June 30, 2026 is low for a mortgage REIT, but GAAP leverage of 13.4× counts the $6.3 billion of non-recourse securitized financing in the $7.3 billion total — the gap between the two is the structure to watch, especially with the Cherry Hill acquisition pending.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.